Adaptimmune Therapeutics PLC — Director's Dealing 2020

Dec 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-12-14

Reporting Person: Bertrand William C JR (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-14	Ordinary Shares with a nominal value of GBP0.001 per share	P	207000	$0.6948	Acquired	284808	Direct

Footnotes

F1: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by William Bertrand. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs.

F3: The price reported in Column 4 of $0.6948 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1688 per ADS divided by six. The purchase price per ADS is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $4.14 to $4.17, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs purchased at each separate price within the range set forth in this footnote.

F4: The 284,808 ordinary shares reported in Column 5 include 77,808 ordinary shares represented by 12,968 ADSs owned by Mr. Bertrand prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Bertrand.